Tech Company Financing Transactions
Terrestrial Bio Funding Round
On 11/2/2022, Terrestrial Bio raised $27 million in Series B funding from RA Capital and private investors.
Transaction Overview
Company Name
Announced On
11/2/2022
Transaction Type
Venture Equity
Amount
$27,000,000
Round
Series B
Investors
RA Capital (Lead Investor) (Mario Barro)
Proceeds Purpose
The money helped the company finally begin the first clinical trial of its technology in August.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
127 Western Ave.
Boston, MA 02134
USA
Boston, MA 02134
USA
Phone
Website
Email Address
Not Recorded
Overview
Terrestrial Bio, Inc. (formerly Vaxess Technologies) is a clinical-stage biotechnology company focused on transforming the delivery of next-generation therapies. The company aims to make therapeutic delivery more patient-friendly and accessible by replacing traditional needles with its proprietary MIMIX� microarray patch (MAP) platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel Sha
Chief Technical Officer
Mark Tracy
Co-Founder
Fiorenzo Omenetto
VP - Bus. Development
Livio Valenti
VP - R & D
Jonathan Kluge
VP - R & D
Kathryn Kosuda
Browse more venture capital transactions:
Prev: 11/2/2022: Volta Greentech venture capital transaction
Next: 11/2/2022: Carta Healthcare venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs